Drugs that contain Letermovir
1. Prevymis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(26 days from now) | |
| US7196086 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(26 days from now) | |
| USRE46791 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(26 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| New Indication(I-916) | Jun 05, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS; TABLET;ORAL
More Information on Dosage
PREVYMIS family patents
